Published in Arch Ophthalmol on March 01, 2010
Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol (2011) 1.25
Vision and vision-related outcome measures in multiple sclerosis. Brain (2014) 1.08
Optic neuritis. Eye (Lond) (2011) 1.05
Visual fields in neuro-ophthalmology. Indian J Ophthalmol (2011) 0.91
Baseline visual field findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci (2014) 0.87
Optic neuritis. J Ophthalmic Vis Res (2010) 0.83
The afferent visual pathway: designing a structural-functional paradigm of multiple sclerosis. ISRN Neurol (2013) 0.82
Comparison of optical coherence tomography and scanning laser polarimetry measurements in patients with multiple sclerosis. Optom Vis Sci (2010) 0.80
Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev (2015) 0.79
Retinal architecture and mfERG: Optic nerve head component response characteristics in MS. Neurology (2014) 0.78
Visual field impairment captures disease burden in multiple sclerosis. J Neurol (2016) 0.76
Visual field characteristics in neuromyelitis optica in absence of and after one episode of optic neuritis. Clin Ophthalmol (2013) 0.76
Retinal ganglion cell and axonal loss in optic neuritis: risk factors and visual functions. Eye (Lond) (2016) 0.75
Visual Field Outcomes for the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). Invest Ophthalmol Vis Sci (2016) 0.75
Optic neuritis as an early sign of multiple sclerosis. Eye Brain (2016) 0.75
Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol (2017) 0.75
Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology (2007) 4.72
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol (2008) 3.92
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol (2005) 3.45
Baseline visual field profile of optic neuritis. The experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Arch Ophthalmol (1993) 2.03
Relation of vision to global and regional brain MRI in multiple sclerosis. Neurology (2007) 1.89
Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol (2003) 1.76
Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol (2008) 1.75
Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. Ocular Hypertension Treatment Study Group. Arch Ophthalmol (2000) 1.62
Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology (2007) 1.56
Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology (2002) 1.46
Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology (2007) 1.46
The relationship between visual field and retinal nerve fiber layer measurements in patients with multiple sclerosis. Invest Ophthalmol Vis Sci (2007) 1.25
Reproducibility of optical coherence tomography in multiple sclerosis. Arch Neurol (2008) 1.25
Is optical coherence tomography really a new biomarker candidate in multiple sclerosis?--A structural and functional evaluation. Invest Ophthalmol Vis Sci (2007) 1.23
Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol (2008) 1.17
The association between glaucomatous visual fields and optic nerve head features in the Ocular Hypertension Treatment Study. Ophthalmology (2006) 1.16
Visual field profile of optic neuritis. One-year follow-up in the Optic Neuritis Treatment Trial. Arch Ophthalmol (1994) 1.14
Recovery of visual field function in the optic neuritis treatment trial. Am J Ophthalmol (1999) 1.13
Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. Am J Ophthalmol (1999) 1.13
A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology (2008) 1.02
The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol (2008) 1.02
Visual field defects in optic neuritis and anterior ischemic optic neuropathy: distinctive features. Graefes Arch Clin Exp Ophthalmol (1998) 0.99
Visual field quality control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma (2007) 0.97
Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). Control Clin Trials (1993) 0.97
Normal visual field test results following glaucomatous visual field end points in the Ocular Hypertension Treatment Study. Arch Ophthalmol (2005) 0.95
Visual field defects in acute optic neuritis--distribution of different types of defect pattern, assessed with threshold-related supraliminal perimetry, ensuring high spatial resolution. Graefes Arch Clin Exp Ophthalmol (2008) 0.86
Retinal involvement in multiple sclerosis. Neurology (2007) 0.82
Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med (2008) 17.19
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 16.89
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol (2002) 11.38
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol (2003) 9.99
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
A randomized trial of patching regimens for treatment of moderate amblyopia in children. Arch Ophthalmol (2003) 5.27
The effect of continuous glucose monitoring in well-controlled type 1 diabetes. Diabetes Care (2009) 4.93
A randomized trial of prescribed patching regimens for treatment of severe amblyopia in children. Ophthalmology (2003) 4.88
Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol (2005) 4.38
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol (2008) 3.92
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology (2007) 3.49
A randomized trial of atropine regimens for treatment of moderate amblyopia in children. Ophthalmology (2004) 3.48
Two-year follow-up of a 6-month randomized trial of atropine vs patching for treatment of moderate amblyopia in children. Arch Ophthalmol (2005) 3.42
Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol (2007) 3.18
High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol (2003) 3.13
The accuracy of the FreeStyle Navigator continuous glucose monitoring system in children with type 1 diabetes. Diabetes Care (2007) 3.11
Continuous glucose monitoring in children with type 1 diabetes. J Pediatr (2007) 3.06
Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med (2011) 2.98
Treatment of anisometropic amblyopia in children with refractive correction. Ophthalmology (2006) 2.89
Factors predictive of use and of benefit from continuous glucose monitoring in type 1 diabetes. Diabetes Care (2009) 2.85
Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther (2013) 2.85
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol (2009) 2.84
Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus. J Pediatr (2005) 2.83
Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch Ophthalmol (2010) 2.78
Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care (2013) 2.73
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes (2005) 2.64
Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology (2007) 2.58
A randomized trial to evaluate 2 hours of daily patching for strabismic and anisometropic amblyopia in children. Ophthalmology (2006) 2.51
Retinal nerve fiber layer thickness in amblyopic eyes. Am J Ophthalmol (2009) 2.29
A randomized trial of atropine vs patching for treatment of moderate amblyopia: follow-up at age 10 years. Arch Ophthalmol (2008) 2.26
The effect of donor age on corneal transplantation outcome results of the cornea donor study. Ophthalmology (2008) 2.19
Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol (2010) 2.14
Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care (2013) 2.03
Prevention of hypoglycemia during exercise in children with type 1 diabetes by suspending basal insulin. Diabetes Care (2006) 2.02
Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol (2004) 2.01
The effects of aerobic exercise on glucose and counterregulatory hormone concentrations in children with type 1 diabetes. Diabetes Care (2006) 1.95
Donor age and corneal endothelial cell loss 5 years after successful corneal transplantation. Specular microscopy ancillary study results. Ophthalmology (2008) 1.94
Baseline donor characteristics in the Cornea Donor Study. Cornea (2005) 1.92
Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab (2013) 1.92
Treatment of severe amblyopia with weekend atropine: results from 2 randomized clinical trials. J AAPOS (2009) 1.89
Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol (2008) 1.87
Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses. Arch Ophthalmol (2004) 1.80
Patching vs atropine to treat amblyopia in children aged 7 to 12 years: a randomized trial. Arch Ophthalmol (2008) 1.80
Neuroanatomical correlates of dysglycemia in young children with type 1 diabetes. Diabetes (2013) 1.78
Clinical profile and early surgical complications in the Cornea Donor Study. Cornea (2006) 1.77
Classification of visual field abnormalities in the ocular hypertension treatment study. Arch Ophthalmol (2003) 1.76
Reliability of the electronic early treatment diabetic retinopathy study testing protocol in children 7 to <13 years old. Am J Ophthalmol (2003) 1.76
Accuracy of newer-generation home blood glucose meters in a Diabetes Research in Children Network (DirecNet) inpatient exercise study. Diabetes Technol Ther (2005) 1.75
Limitations of statistical measures of error in assessing the accuracy of continuous glucose sensors. Diabetes Technol Ther (2005) 1.74
Primary treatment of nasolacrimal duct obstruction with probing in children younger than 4 years. Ophthalmology (2007) 1.73
Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol (2009) 1.72
Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment. Arch Ophthalmol (2004) 1.71
Accuracy of the modified Continuous Glucose Monitoring System (CGMS) sensor in an outpatient setting: results from a diabetes research in children network (DirecNet) study. Diabetes Technol Ther (2005) 1.70
Specular microscopy ancillary study methods for donor endothelial cell density determination of Cornea Donor Study images. Curr Eye Res (2006) 1.65
Treatment of bilateral refractive amblyopia in children three to less than 10 years of age. Am J Ophthalmol (2007) 1.64
Evaluation of the structure-function relationship in glaucoma. Invest Ophthalmol Vis Sci (2005) 1.64
Quantitation of cardiolipin molecular species in spontaneously hypertensive heart failure rats using electrospray ionization mass spectrometry. J Lipid Res (2005) 1.61
Risk of amblyopia recurrence after cessation of treatment. J AAPOS (2004) 1.59
Pulsar perimetry in the diagnosis of early glaucoma. Am J Ophthalmol (2009) 1.57
Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology (2007) 1.56
Impact of patching and atropine treatment on the child and family in the amblyopia treatment study. Arch Ophthalmol (2003) 1.56
The Nature of Macular Damage in Glaucoma as Revealed by Averaging Optical Coherence Tomography Data. Transl Vis Sci Technol (2012) 1.55
Primary treatment of nasolacrimal duct obstruction with nasolacrimal duct intubation in children younger than 4 years of age. J AAPOS (2008) 1.55
Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry. Pediatr Diabetes (2013) 1.54
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology (2011) 1.52
Normative ranges and specificity of the multifocal VEP. Doc Ophthalmol (2004) 1.52
Neurologic impairment 10 years after optic neuritis. Arch Neurol (2004) 1.51
Recent advances in the treatment of amblyopia. Pediatrics (2004) 1.51
A randomized trial comparing Bangerter filters and patching for the treatment of moderate amblyopia in children. Ophthalmology (2010) 1.47
Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Arch Ophthalmol (2012) 1.47
Baseline visual field characteristics in the ocular hypertension treatment study. Ophthalmology (2002) 1.46
Comparison of different methods for detecting glaucomatous visual field progression. Invest Ophthalmol Vis Sci (2003) 1.46
Sample size for a clinical trial: why do some trials need only 100 patients and others 1000 patients or more? Ophthalmology (2006) 1.46
An evaluation of image quality and accuracy of eye bank measurement of donor cornea endothelial cell density in the Specular Microscopy Ancillary Study. Ophthalmology (2005) 1.43
Recipient risk factors for graft failure in the cornea donor study. Ophthalmology (2009) 1.40
Registration of clinical trials. Arch Ophthalmol (2005) 1.39
Primary treatment of nasolacrimal duct obstruction with balloon catheter dilation in children younger than 4 years of age. J AAPOS (2008) 1.36
Frequency-doubling technology perimetry. Ophthalmol Clin North Am (2003) 1.34
A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology (2010) 1.34
Identification of progressive glaucomatous visual field loss. Surv Ophthalmol (2002) 1.33
Properties of perimetric threshold estimates from full threshold, ZEST, and SITA-like strategies, as determined by computer simulation. Invest Ophthalmol Vis Sci (2003) 1.30
Performance comparison of the medtronic sof-sensor and enlite glucose sensors in inpatient studies of individuals with type 1 diabetes. Diabetes Technol Ther (2013) 1.29
Variation of interstitial glucose measurements assessed by continuous glucose monitors in healthy, nondiabetic individuals. Diabetes Care (2010) 1.29